Taken together, our studies provide a mechanism and indicate that Ets-1/GPX2 axis mediates sorafenib resistance in HCC, targeting of which in the future might help in ameliorating resistance and increasing sorafenib efficacy. The gene discussed is GPX2; the disease is hepatocellular carcinoma.